Description
An inhibitor of VMAT2 that is selective over VMAT1 (Kis = 97 and >20,000 nM, respectively, in a serotonin uptake assay); dose-dependently reduces levels of the monoamines norepinephrine, dopamine, and 5-HT in rat brain; has been used to induce depressive-like behavior in animal models; improves performance in balance beam and rotarod tests and prevents decreases in the number of striatal MSNs in a YAC128 transgenic mouse model of Huntington’s disease at 5 mg/kg
Formal name: rel-1,3R,4,6,7,11bR-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-one
Synonyms: NSC 169886|NSC 172187|Ro 1-9569|TBZ
Molecular weight: 317.4
CAS: 58-46-8
Purity: ≥98% (mixture of enantiomers)
Formulation: A crystalline solid
Product Type|Biochemicals|Transporter & Exchanger Modulators||Research Area|Neuroscience|Behavioral Neuroscience|Depression||Research Area|Neuroscience|Neurodegenerative Disorders|Huntington’s Disease||Research Area|Neuroscience|Neuroprotection